Methods and kits for cell activation
Provided are methods and kits for activating T cells, the method comprising providing a population of T cells, adding a plurality of first agents, where the first agent comprises a T-cell activator and a first binder moiety, and adding a second agent comprising a plurality of capture oligomers, where at least a segment of at least one of the plurality of capture oligomers is capable of associating with the first binder moiety. The method further comprises incubating the population of T cells, whereby at least a portion of the population of T cells is activated.
1. A method of activating T cells, the method comprising:
a) providing a population of T cells;
b) adding a plurality of first agents, wherein the first agent comprises a T-cell activator attached to a first binder moiety;
c) adding a second agent comprising a plurality of capture oligomers, wherein at least a segment of at least one of the plurality of capture oligomers is capable of associating with the first binder moiety; and
d) incubating the population of T cells after steps (b) and (c), whereby at least a portion of the population of T cells is activated.
2. The method of claim 1 , wherein the second agent is a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences.
3. The method of claim 2 , wherein the second agent is a rolling circle amplification product comprising a plurality of capture oligonucleotide sequences.
4. The method of claim 2 , wherein the first binder moiety is a nucleic acid sequence, wherein at least a segment of at least one of the plurality of capture oligonucleotide sequences is complementary to the nucleic acid sequence.
5. The method of claim 2 , further comprising adding a nuclease.
6. The method of claim 1 , wherein the T-cell activator is an anti-CD3 antibody or a fragment thereof.
7. The method of claim 1 , further comprising adding a T-cell co-stimulator.
8. The method of claim 7 wherein the T-cell co-stimulator is an anti-CD28 antibody, an anti-CD2 antibody or fragments thereof.
9. The method of claim 7 , wherein the T-cell co-stimulator is attached to a second binder moiety, wherein at least a segment of at least one of the plurality of capture oligomers is capable of associating with the second binder moiety.
10. The method of claim 9 , wherein the second binder moiety is a nucleic acid sequence.
11. The method according to claim 7 where the T-cell activator is an anti-CD3 antibody attached to a nucleic acid sequence, the T-cell co-stimulator is an anti-CD28 antibody attached to a nucleic acid sequence, and the second agent is a rolling circle amplification product comprising of a plurality of complementary capture oligonucleotide sequences.
12. A method according to claim 1 , further comprising a step of adding a vector comprising a foreign gene into the population of T cells.
13. A method according to claim 12 , wherein the vector is added with the plurality of first agents.
14. A method according to claim 12 , wherein the vector is added after at least a portion of the population of T cells is activated.
15. A method according to claim 12 , wherein the vector is a lentivirus vector or a gamma-retrovirus vector.
16. The method of claim 1 ,
wherein the T-cell activator is an anti-CD3 antibody, the first binder moiety is a nucleic acid sequences, the second agent is a nucleic acid polymer and the plurality of capture oligomers is a plurality of capture oligonucleotide sequences, wherein at least a segment of at least one of the plurality of capture oligonucleotide sequences is complementary to the nucleic acid sequence attached to the anti-CD3 antibody.
17. The method of claim 16 , further comprising adding an anti-CD28 antibody.
18. The method of claim 17 , wherein the anti-CD28 antibody is attached to a nucleic acid sequence, wherein at least a segment of at least one of the plurality of capture oligonucleotide sequences is complementary to the nucleic acid sequence attached to the anti-CD28 antibody.
19. The method of claim 2 , wherein the number of capture oligonucleotide sequences in the nucleic acid polymer is greater than 3.
20. The method of claim 2 , wherein the plurality of capture oligonucleotide sequences have the same nucleotide sequence or have different nucleotide sequences.
21. A method of activating cells, the method comprising:
a) providing a population of cells selected from the group consisting of B cells, T cells and natural killer cells;
b) adding a plurality of first agents, wherein the first agent comprises a cell activator attached to a first binder moiety:
c) adding a second agent comprising a plurality of capture oligomers, wherein at least a segment of at least one of the plurality of capture oligomers is capable of associating with the first binder moiety; and
d) incubating the population of cells after steps (b) and (c), whereby at least a portion of the population of cells is activated.
22. The method of claim 21 , wherein the second agent is a nucleic acid polymer comprising a plurality of capture oligonucleotide sequences.
23. The method of claim 22 , wherein the second agent is a rolling circle amplification product comprising a plurality of capture oligonucleotide sequences.
24. The method of claim 22 , wherein the first binder moiety is a nucleic acid sequence, wherein at least a segment of at least one of the plurality of capture oligonucleotide sequences is complementary to the nucleic acid sequence.
25. The method of claim 24 , wherein the cell activator is attached to the nucleic acid sequence via a covalent attachment.